Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical application of the AMOY 9-in-1 panel to lung cancer patients.

Lung cancer (Amsterdam, Netherlands) - 1 May 2023

Kunimasa Kei, Matsumoto Shingo, Kawamura Takahisa, Inoue Takako, Tamiya Motohiro, Kanzaki Ryu, Maniwa Tomohiro, Okami Jiro, Honma Keiichiro, Goto Koichi, Nishino Kazumi

Abstract excerpt

INTRODUCTION: To investigate the clinical performance of the AMOY 9-in-1 kit (AMOY) in comparison with a next-generation sequencing (NGS) panel in lung cancer patients. METHODS: Lung cancer patients enrolled in the LC-SCRUM-Asia program at a single institution were analyzed for the success rate of AMOY analysis, the detection rate of targetable driver mutations, the turn around time (TAT) from specimen submission...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 37058787
DOI: 10.1016/j.lungcan.2023.107190

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical application of the AMOY 9-in-1 panel to lung cancer patients.PMID 37058787Read ↗

Suitability of frozen cell pellets from cytology specimens for the Amoy 9-in-1 assay in patients with non-small cell lung cancer.Semantic proximity Read ↗

The Race Against Time: Evaluating the Speed of Gene Panel Result Delivery in NSCLC Patient ManagementSemantic proximity Read ↗

Multicenter Evaluation of the Idylla GeneFusion in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Evaluation of turnaround times and performance of in-house ChromaCode high-definition PCR compared to send-out next-generation sequencing in non-small cell lung cancer.Semantic proximity Read ↗

Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer.Semantic proximity Read ↗

Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma.Semantic proximity Read ↗

The Current Achievements of Multi-Gene Panel Tests in Clinical Settings for Patients with Non-Small-Cell Lung CancerSemantic proximity Read ↗

Same-day molecular testing for targetable mutations in solid tumor cytopathology-The next frontier of the rapid on-site evaluation.Semantic proximity Read ↗

Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.Semantic proximity Read ↗

Retrospective Comparison of Operational Metrics Across Diagnostic Approaches for Molecular Testing in Lung and Colon Cancers in a Community-Based Setting.Semantic proximity Read ↗

Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLCSemantic proximity Read ↗

Integrating the Idylla™ System Alongside a Real-Time Polymerase Chain Reaction and Next-Generation Sequencing for Investigating Gene Fusions in Pleural Effusions from Non-Small-Cell Lung Cancer Patients: A Pilot Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.